Skip to main content
Premium Trial:

Request an Annual Quote

Cedric Loiret-Bernal, Deborah Neff, Michael Kranda, Robert Ellis, Colin Brenan, Terrance Bieker, Len Hendrickson, Robert Weltman, Robert Rosenthal, John Canepa


Cedric Loiret-Bernal has become the president and CEO of Nanolink, a Chicago-based company that makes nanofabricated devices. Loire-Bernal was previously CEO of Geneva Proteomics, which he co-founded. He most recently held a position at CDP Capital Technology Ventures, a Canadian investment company. Prior to founding GeneProt, Loiret-Bernal was a partner and senior investment analyst at Brinson Partners, now part of UBS. He holds a medical degree from the University of Bordeaux and an MBA from Northwestern University.

Deborah Neff has become president and CEO of Biospect, the South San Francisco, Calif.-based biomarker company said this week. Neff was most recently worldwide president of BD Biosciences.

Michael Kranda has been appointed to the investment management team of Vulcan, which handles Paul Allen’s investments. Kranda was previously CEO of Oxford GlycoSciences. Prior to that, he was president and chief operating officer and director at Immunex.

Robert Ellis has become president and CEO of BioTrove, and former CEO Colin Brenan has become chief technology officer and senior vice president, the Woburn, Mass.-based company announced this week. Ellis was previously chief operating officer at BioTrove. Before that, he was an executive vice president at Affymetrix. Prior to that, he was president of Genometrix and President of Applied Biosystems Japan. He also worked in R&D for PerkinElmer. Ellis holds a BA in chemistry from Hartwick College.

Terrance Bieker has been named president and CEO of BioSource, of Camarillo, Calif. Bieker will replace Len Hendrickson, who resigned for an indefinite medical disability leave of absence in early September. Robert Weltman, who is currently on the board of directors, will serve as the interim CEO through November. Bieker was formerly CEO of Axya Medical, and president and CEO of Transfusion Technologies. He has also served as executive vice president and chief operation officer of Safeskin; chairman, CEO and president of Sanofi Diagnostics Pasteur; and general manager of Genetic Systems.

Robert Rosenthal has been appointed president and CEO of Hop-kinton, Mass.-based TekCel. Rosenthal was formerly president of PerkinElmer’s instrument’s division, which the company combined with life sciences a year ago. Prior to that, Rosenthal was president and CEO of Thermo Optek, an instrument company that went public in 1996. Before that, he was president of Nicolet Instrument, a subsidiary of Thermo Instruments. Rosenthal replaces Herbert Hooper, who is an operating partner at Ampersand Ventures, the lead investor in the company, and was serving as interim CEO of TekCel since August 2003.

John Canepa has been appointed vice president of finance and chief financial officer of US Genomics. Before joining the Woburn, Mass., company, Canepa served as vice president of finance and administration and chief financial officer at Winphoria Networks, a telecommunications company that was sold to Motorola. Prior to that, Canepa was a senior partner in the Boston office of Arthur Andersen, and led Andersen’s life sciences practice.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.